Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity

被引:19
|
作者
Lundstrom, K
Hawcock, AB
Vargas, A
Ward, P
Thomas, P
Naylor, A
机构
[1] GLAXO WELLCOME RES & DEV LTD,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND
[2] GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND
关键词
Semliki Forest virus system; tachykinin NK1 receptor; mutagenesis; site-directed; binding assays; functional coupling;
D O I
10.1016/S0014-2999(97)01226-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Molecular modelling and site-directed mutagenesis were used to identify eleven amino acid residues which may be involved in antagonist binding of the human tachykinin NK1 receptor. Recombinant receptors were expressed in mammalian cells using the Semliki Forest virus system. Wild type and mutant receptors showed similar expression levels in BHK and CHO cells, verified by metabolic labelling Binding affinities were determined for a variety of tachykinin NK1 receptor antagonists in SFV-infected CHO cells. The binding affinity for GR203040, CP 99,994 and CP 96,345 was significantly reduced by mutant Q165A. The mutant F268A significantly reduced the affinity for GR203040 and CP 99,994 and the mutant H197A had reduced affinity for CP 96,345. All antagonists seemed to bind in a similar region of the receptor, but do not all rely on the same binding site interactions. Functional coupling to G-proteins was assayed by intracellular Ca2+ release in SFV-infected CHO cells. The wild type receptor and all mutants except A162L and F268A responded to substance P stimulation. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 50 条
  • [1] Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity
    Hawcock, AB
    Lundstrom, K
    Thomas, P
    Naylor, A
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P328 - P328
  • [2] Opioid activity of sendide, a tachykinin NK1 receptor antagonist
    Sakurada, T
    Yuhki, M
    Inoue, M
    Sakurada, C
    Koichi, TN
    Ohba, M
    Kisara, K
    Sakurada, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 369 (03) : 261 - 266
  • [3] MEN 11149, a potent antagonist of the tachykinin NK1 receptor
    Astolfi, M
    Parlani, M
    Lopez, G
    Conte, B
    Cirillo, R
    Fincham, CI
    Terracciano, R
    Manzini, S
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P202 - P202
  • [4] Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist
    Cascieri, MA
    Ber, E
    Fong, TM
    Hale, JJ
    Tang, F
    Shiao, LL
    Mills, SG
    MacCoss, M
    Sadowski, S
    Tota, MR
    Strader, CD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (2-3) : 253 - 261
  • [5] Crystal structure of the human NK1 tachykinin receptor
    Yin, Jie
    Chapman, Karen
    Clark, Lindsay D.
    Shao, Zhenhua
    Borek, Dominika
    Xu, Qingping
    Wang, Junmei
    Rosenbaum, Daniel M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (52) : 13264 - 13269
  • [6] The human tachykinin, NK1 (short form) and tachykinin NK4 receptor:: a reappraisal
    Page, NM
    Bell, NJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 437 (1-2) : 27 - 30
  • [7] Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor:: evidence from quantitation of receptor endocytosis
    Jenkinson, KM
    Southwell, BR
    Furness, JB
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) : 131 - 136
  • [8] CYCLOSPORINE-A IS A SUBSTANCE-P (TACHYKININ NK1) RECEPTOR ANTAGONIST
    GITTER, BD
    WATERS, DC
    THRELKELD, PG
    LOVELACE, AM
    MATSUMOTO, K
    BRUNS, RF
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 289 (03): : 439 - 446
  • [9] INVESTIGATION OF THE SPECIFICITY OF FK-888 AS A TACHYKININ NK1 RECEPTOR ANTAGONIST
    WANG, ZY
    TUNG, SR
    STRICHARTZ, GR
    HAKANSON, R
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (04) : 1342 - 1346
  • [10] Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret
    Minami, M
    Endo, T
    Kikuchi, K
    Ihira, E
    Hirafuji, M
    Hamaue, N
    Monma, Y
    Sakurada, T
    Tan-No, K
    Kisara, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 363 (01) : 49 - 55